MPN-467 Findings From an Observational, Multicenter, Retrospective Analysis of Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With Tagraxofusp in the European Expanded Access Program.

Fiche publication

Date publication

octobre 2022

Journal

Clinical lymphoma, myeloma & leukemia

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DECONINCK Eric

Tous les auteurs :
Herling M, Deconinck E, Anant M, Manteigas D, Riggi M, Mughal T, Angelucci E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36164010

Résumé

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic malignancy with poor prognosis, is characterized by clonal expansion of plasmacytoid dendritic tumor cells expressing specific markers including the interleukin-3 receptor alpha (CD123). Tagraxofusp (TAG) is a CD123-targeted therapy approved by the FDA and EMA. A global expanded access program (EAP) was implemented prior to TAG's EMA authorization to provide access to patients in real-world practice.